We are delighted to welcome Immunodiagnostic Systems Holding (IDS) as the newest member of the PerkinElmer family. The acquisition of the British diagnostics company was officially closed in July 2021. In future, IDS and EUROIMMUN will closely cooperate in the fields of research and development, production as well as distribution.

IDS is a leading company for in vitro diagnostics and has more than 30 years of market expertise. Today, close to 300 employees worldwide develop and distribute high-quality random-access automation solutions, chemiluminescence immunoassays and ELISAs for the areas of endocrinology and autoimmune, infection and allergy diagnostics.

IDS’ competence and expertise in  research and product development as well as their large product range ideally complement EUROIMMUN’s know-how and portfolio.

“The cooperation of our distribution channels and the expansion of our product portfolio will strengthen our joint presence in the diagnostics market. Our customers will benefit from our partnership with IDS due to the broader range of assays and laboratory workflows, especially in the area of random-access- and chemiluminescence-based diagnostics”, says Dr Wolfgang Schlumberger, EUROIMMUN’s CEO.

“I am very pleased IDS have joined the PerkinElmer family. This will allow IDS to significantly accelerate our existing growth plans, while providing exciting new opportunities for our employees, customers, partners and suppliers. EUROIMMUN have been a valued partner of IDS for many years, and this will allow us to co-operate jointly to continuously provide innovative diagnostic solutions to both existing and new customers around the globe. I am excited and confident that this cooperation represents an excellent opportunity for all stakeholders”, says Jaap Stuut, CEO of IDS.